Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Want to see PCVX full AI Analyst Report?
PCVX Stock Chart & Stats
$62.35
-$2.14(-2.45%)
At close: 4:00 PM EST
$62.35
-$2.14(-2.45%)
Day’s Range― - ―
52-Week Range$29.08 - $65.00
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.61M
Market Cap
$7.16B
Enterprise Value$6.98B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$116.30M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 12, 2026EPS Estimate
-1.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.89
Shares Outstanding144,397,670
10 Day Avg. Volume1,352,099
30 Day Avg. Volume1,611,432
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.19K
Enterprise Value/Ebitda-7.58
Forecast
1Y Price Target
$116.00Price Target Upside86.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-8.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVaxcyte's sizable equity and low historical debt-to-equity (~0.02–0.09; ~0.04 TTM) provide durable financial flexibility. That balance-sheet cushion supports multi-year clinical programs, gives optionality for partnerships or M&A, and reduces near-term solvency risk while R&D progresses.
Pipeline AdvancementDosing the first participant in a first-in-human study represents structural pipeline de-risking and program progression beyond pneumococcal candidates. A new clinical program broadens the therapeutic scope, creates potential milestone/licensing triggers, and enhances long-term value if safety and immunogenicity are demonstrated.
Governance ContinuityRe-election of directors and ratification of Deloitte as auditor signal investor support for management and oversight continuity. Stable governance reduces execution risk for multi-year trials, aids predictable strategic planning, and supports consistent engagement with partners and regulators over the clinical development timeline.
Bears Say
No Product RevenueVaxcyte remains a development-stage biotech with no commercial revenues, so operating performance depends entirely on R&D success and external funding. The absence of product cash flows means longevity hinges on financing or partnerships rather than internal cash generation, raising structural execution risk.
Escalating LossesRapidly widening net losses reflect an expanding expense base to fund trials and pipeline activities. Sustained growing losses increase required external financing, magnify dilution risk, and compress managerial flexibility to prioritize projects, making long-term program completion contingent on continued capital access.
High Cash Burn / Negative FCFConsistently deep negative operating and free cash flow necessitate recurrent capital raises or partner funding. Large cash burn limits runway, can force project prioritization or delays, and elevates refinancing and dilution risk—structural constraints for a company without commercial revenues.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $29.08 and its highest was $65.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $7.16B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 06, 2026. The company reported -$2.3 earnings per share for the quarter, missing the consensus estimate of -$1.741 by -$0.559.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.99.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 144,397,670 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$2.3 in its last earnings report, missing expectations of -$1.741. Following the earnings report the stock price went down -9.842%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$116.00 (86.05% Upside)
$116.00 (86.05% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
43.40%
12-Months-Change
Fundamentals
Return on Equity
-32.51%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
PCVX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.View all PCVX earnings summariesPCVX Stock 12 Month Forecast
Average Price Target
$116.00
▲(86.05% Upside)
Technical Analysis
Ownership Overview
0.88% Insiders
35.99% Mutual Funds
46.62% Other Institutional Investors
0.44% Public Companies and
Individual Investors